VaxGen plans to relist shares

South San Francisco biopharmaceutical firm VaxGen Inc. (Pink sheets: VXGN) said it is now current on its financial reporting obligations with the U.S. Security and Exchange Commission and plans to relist its common stock on a nationally recognized stock exchange.

VaxGen has suffered a series of setbacks.

The company, which suffered a well publicized failure of an AIDS vaccine it was developing in 2003, was delisted from the Nasdaq exchange in 2004 for failing to promptly file financial reports with federal authorities as required. It then lost a U.S. government contract to provide an anthrax vaccine in December 2006 after missing a key deadline.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

The most dangerous behaviors by drivers include failing to yield right-of-way at crosswalks, unsafe speeding and failing to stop at red lights or stop signs. <ins>(Ekevara Kitpowsong/Special to S.F. Examiner)</ins>
Hetch Hetchy in Yosemite, which supplies water to San Francisco, is among the concerns of the San Francisco Public Utilities Commission, which is undergoing a change of leadership. <ins>(Courtesy SFPUC)</ins>
Changes at SFPUC spark concern, hope

Will agency’s new commissioner continue to support Big Ag?

A screenshot from SFPD body worn camera
New videos show police shooting man armed with knife, frying pan

Police say Antonio Estrada set fire to apartment building before shooting

Dr. Grant Colfax, director of the Department of Public Health, said he expected San Francisco to enter the purple tier within days.
Chris Victorio/Special to S.F. Examiner
SF still in the red but expects move into purple tier ‘some time soon’

Four more counties moved into highest COVID-19 risk category by state

Most Read